3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
1
Interventions
Injections
17
Cisplatin
15
Carboplatin
15
Oxaliplatin
11
Gemcitabine
11
pembrolizumab
8
Capecitabine
8
toripalimab
7
Paclitaxel
7
Etoposide
7
Cyclophosphamide
7
Pemetrexed
6
Irinotecan
6
Drug Therapy
6
spartalizumab
5
fludarabine
5
camrelizumab
5
Vincristine
5
Radiotherapy
5
Leucovorin
5
tislelizumab
4
apatinib
4
anlotinib
4
Interleukin-2
4
Immune Checkpoint Inhibitors
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Fluorouracil
4
Docetaxel
4
Bevacizumab
4
tremelimumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Olanzapine
×
Other solid neoplasm
×
Clear all
NCT04536558
2020-09-02
OFFER
Sun Yat-sen University
Phase 3
Unknown
352 enrolled